Page 28 - Pharma Industry

Pharma firms plan awareness drive to battle cancer scare in antacid

Indian companies have also been hit in their global business.

Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad

According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact

China opens public hospitals for Dr Reddy's Laboratories generic drugs

First Indian firm to get contract for supplying generic schizophrenia drug to public hospitals there

Unichem gets USFDA approval for high blood pressure drug Chlorthalidone

Unichem said the product will be commercialised from its Ghaziabad plant

Natco Pharma's API facility near Hyderabad gets 6 USFDA observations

The company said that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust

Aurobindo to Jubilant Life Sciences, drug makers face USFDA heat

Some of the inspections have not yet received a final classification, which raises the potential for OAIs

Bulk drug exports rise as Indian makers cash in on China's regulatory woes

Iran emerged as a major destination in FY19 with 68% growth after registering negative growth in FY17 and FY18

From Lupin to Dr. Reddy's, year may end on a good note for pharma firms

During the previous quarter too, the Indian drug firms had reported a better than expected performance in the US

Drugmakers make lowest return on R&D investments in 9 years: Deloitte

LONDON (Reuters) - The cost of developing a new drug has nearly doubled since 2010 and the world's 12 biggest drugmakers are making the lowest return on their R&D investments in nine years, according to Deloitte.

Hypertension drug recall by USFDA shot in the arm for some drug majors

The recall was due to an impurity (N-Nitrosodimethylamine or NDMA) which was found in the recalled products that include valsartan and its combinations

Falling rupee to boost pharma top lines, margins in Q2: India Ratings

However, drug firms focussed on domestic market would post muted growth in Q2FY19 on a year-on-year basis

USFDA generic guidance to help local pharma formulators with ANDA approvals

The recent guidance from the US Food & Drug Administration (USFDA) on complex generics is expected to provide more clarity to US-focused Indian pharmaceutical formulators in preparing and submitting abbreviated new drug applications (ANDAs), says a report. This will help domestic pharma formulators with pending ANDA approvals to reduce review cycles and expedite approvals, says a weekend report by India Ratings. The current guidance dated October 9 is specific to complex transdermal and topical products. The agency in its mid-year FY19 pharma outlook had identified the lack of scientific and regulatory clarity about complex drugs as one of the key hurdles for approvals of complex products. Indian pharmaceutical formulators have indicated low double-digit pricing erosion for their base portfolio at end-FY18 and were exiting highly generic commercially unviable products and pruning R&D pipeline. The regulatory clarity will benefit formulators such as Lupin ...

E-pharmacy deal values surge over 200% in first nine months of 2018

Mumbai, 2 OctoberThe pharmaceutical and online pharmacy space seems to heating up on private equity (PE) and venture capital (VC) deals. As of end-September, the e-pharmacy space, for example, has seen a 210 per cent jump in deal value, compared to full calendar year 2017. Similarly, nine deals in the pharmaceutical space have surpassed the cumulative deal size for all of 2017.Data from Venture Intelligence shows e-pharmacy had a total of seven deals during January to September, the cumulative value being $115 milion (Rs 8.3 billion). The corresponding period last year had seen only three deals, for a total value of $23 mn. For all of 2017, the space witnessed five deals, totalling $37 mn. Some of the key deals were PharmEasy and Netmeds raising funds from Eight Roads Ventures India, Think Investments, Sistema Asia Fund and others. "PE investors were already active in other sectors. Education and pharmacy were two sectors that saw some initial resistance from investors. However, ...

Rising API prices to hit drug firms' profit by 300-500 bps in 2-3 quarters

In the past few months, the prices of APIs from China have gone up in the range of 15-80 per cent, amid a crackdown by the local government on industries allegedly polluting the environment

Pharmaceutical industry improving inspection skills for better compliance

State-level drug control administrations, too, have geared up to align themselves with global regulators

Industry asks govt not to cap margins on unbranded generics

Govt had received complaints from various quarters that trade margins for drugs range between 300% and 5,000%

Pharma cos may post better results in Q2

Sun Pharma's top-line is likely to decline 15%, owing to increasing pressure on Taro's business

Icra sees moderate growth in pharma industry

BS ReporterHyderabad, 2 October: Research and rating agency ICRA said Indian pharmaceutical industry was likely to register a moderate growth on the back of slowing growth from US given the relatively moderate proportion of large size drugs going off patent, increased competition leading to price erosion, generic adoption reaching saturation levels among other things.Aggregate revenues of ICRA's sample set of 21 leading players declined by 8.8 percent during the first quarter of the financial year 2017-18 vis-a-vis the prior year as against the December-March, 2017 quarter growth at 0.2 percent.The revenue growth has been subdued for the US as well as domestic market in the first quarter with the base business in US continuing to face low to mid teens price erosion, regulatory overhang for select companies and impact of GST implementation on domestic growth.ICRA stated that the negative growth in the first quarter of the current fiscal was led by trade channel destocking initiative ...

Unhedged rupee bets weigh on firms

Rupee rising against dollar and some other currencies has been a pain point for exports

Sluggish US market to pull down domestic Pharma growth to 7-10%: Icra

The growth trajectory for Indian pharmaceutical industry is likely to moderate to 7 to 10 per cent over FY18 to FY20 after mid to high double digit growth over last five years, feels rating agency ICRA. This is on the back of slowing growth from US.ICRA says the growth in US is slowing 'given the relatively moderate proportion of large size drugs going off patent, increased competition leading to price erosion in high single digits to low teens, generic adoption reaching saturation levels and, regulatory overhang along with base effect catching up.'According to Gaurav Jain, vice president and co-head, corporate sector ratings, ICRA , "The growth momentum is likely to face further pressure going forward, led by limited near term first to file (FTF) generic opportunities and pricing pressure on generic base business. Besides increased regulatory scrutiny and consolidation of supply chain in US market resulting in pricing pressures along with increased R&D expenses will also have an .